ClouDr Group Limited (9955) AI Stock Analysis

• Market Cap: HK$887.94M
• Dividend Yield: N/A
• Average Volume (3M): 1.17M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.11
• Revenue Growth: -43.86%
• EPS Growth: -217.25%
• Country: HK
• Employees: 1,218
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Distribution
• EPS (TTM): -1.00
• Shares Outstanding: 645,718,800
• 10 Day Avg. Volume: 766,910
• 30 Day Avg. Volume: 1,166,703
• PEG Ratio: -0.03
• Price to Book (P/B): 0.45
• Price to Sales (P/S): 0.19
• P/FCF Ratio: -2.90
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$1.50
• Price Target Upside: 8.70% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 44 Neutral
• Price Target: HK$1.50 ▲(8.70% Upside)

ClouDr Group Limited's overall stock score is primarily impacted by its financial performance, which shows growth but significant profitability challenges. Technical analysis provides a mixed outlook with some short-term bullish signals, while valuation metrics highlight ongoing losses. The absence of earnings call and corporate events data limits additional insights.

ClouDr Group Limited Business Overview & Revenue Model

Company Description

ClouDr Group Limited, an investment holding company, provides supplies and software as a service (SaaS) to hospitals and pharmacies, digital marketing services to pharmaceutical companies, and online consultation and prescriptions for chronic condition management. It distributes hospital supplies, which include medical devices, such as blood glucose meters and vital sign monitors, glucose testing strips, and OTC and prescription drugs; and hospital and pharmacy SaaS and digital marketing services to pharmaceutical companies. The company also provides real time consultation, digital condition tracking, and online prescription and ordering services. ClouDr Group Limited was founded in 2014 and is headquartered in Hangzhou, China.

How the Company Makes Money

ClouDr Group Limited generates revenue primarily through subscription fees for its cloud-based healthcare platforms and services. The company offers its digital solutions on a subscription basis to hospitals, clinics, and other healthcare providers, enabling them to access and utilize its technology to improve operational efficiency and patient care. Additionally, ClouDr may engage in partnerships with other companies or healthcare institutions to expand its market reach and enhance its service offerings. Revenue can also be supplemented by providing value-added services such as data analytics and customized healthcare IT solutions tailored to the specific needs of its clients.

ClouDr Group Limited Financial Statement Overview

Summary

ClouDr Group Limited is experiencing growth in revenue, but profitability remains a challenge with persistent net losses. Improvements in balance sheet metrics such as leverage and equity ratio are positive signs, yet historical negative equity and high liabilities are concerning. The company’s cash flow situation is precarious, relying heavily on external financing, which could impact future liquidity. Overall, while there are positive signs of growth and improved leverage, profitability and cash flow generation remain key areas of concern.

Income Statement

ClouDr Group Limited shows a consistent increase in revenue over the years, with a significant jump from 2020 to 2021. However, the company is still operating at a loss, with net losses increasing over time. The gross profit margin has remained stable, indicating efficient cost management. The negative EBIT and EBITDA margins highlight ongoing operational challenges, and the declining net income margin raises concerns about profitability in the near term.

Balance Sheet

The company's debt-to-equity ratio has improved over time, suggesting better leverage management. However, the negative stockholders' equity in earlier years indicates historical financial difficulties. The equity ratio has improved, reflecting better asset management. Despite positive trends, the company's past negative equity and high liabilities pose risks.

Cash Flow

Despite generating negative free cash flow consistently, ClouDr Group Limited managed to improve operating cash flow over recent years. The operating cash flow to net income ratio indicates that the company is still struggling with cash generation relative to its income losses. The reliance on financing activities for cash sustenance could pose liquidity risks.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.26B	3.49B	3.69B	2.99B	1.76B	839.12M
Gross Profit	755.69M	861.67M	909.38M	792.10M	570.02M	232.76M
EBITDA	-764.00M	-372.34M	-208.37M	-1.58B	-4.06B	-2.86B
Net Income	-949.68M	-516.41M	-323.06M	-1.69B	-4.14B	-2.87B
Balance Sheet
Total Assets	2.15B	2.84B	2.95B	2.83B	2.51B	1.69B
Cash, Cash Equivalents and Short-Term Investments	559.64M	525.84M	595.10M	723.17M	1.12B	981.42M
Total Debt	558.23M	581.24M	469.69M	228.67M	9.03B	358.62M
Total Liabilities	1.33B	1.41B	1.18B	953.05M	9.66B	5.08B
Stockholders Equity	962.37M	1.45B	1.83B	1.85B	-7.14B	-3.36B
Cash Flow
Free Cash Flow	26.33M	-225.19M	-263.46M	-809.87M	-755.02M	-478.99M
Operating Cash Flow	47.15M	-148.39M	-140.43M	-642.63M	-666.33M	-438.46M
Investing Cash Flow	11.80M	66.87M	-38.34M	-744.94M	-155.50M	-160.20M
Financing Cash Flow	7.56M	147.99M	171.81M	503.55M	1.02B	918.41M

ClouDr Group Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.38
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9955, the sentiment is Positive. The current price of 1.38 is above the 20-day moving average (MA) of 1.37, below the 50-day MA of 1.45, and above the 200-day MA of 1.29, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 50.35 is Neutral, neither overbought nor oversold. The STOCH value of 50.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:9955.

ClouDr Group Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2192	67 Neutral	HK$9.41B	26.84	6.77%	2.21%	29.81%	10.40%
1931	65 Neutral	HK$15.10B	80.26	5.07%	0.96%	0.33%	-44.28%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
9955	44 Neutral	HK$887.94M	―	-69.05%	―	-43.86%	-217.25%

ClouDr Group Limited Corporate Events

ClouDr Group Limited Announces Board Composition

ClouDr Group Limited has announced the composition of its board of directors, which includes both executive and independent non-executive directors. The board is structured with three committees: Audit, Remuneration, and Nomination, each with designated members and roles. This announcement highlights the company’s governance structure, potentially impacting its strategic direction and stakeholder confidence.

The most recent analyst rating on (HK:9955) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on ClouDr Group Limited stock, see the HK:9955 Stock Forecast page.

ClouDr Group Limited Forms Nomination Committee to Enhance Board Governance

ClouDr Group Limited has established a Nomination Committee to identify and recommend candidates for its Board of Directors, oversee Board performance evaluations, and develop nomination guidelines in compliance with relevant laws and regulations. The committee will consist of a majority of independent non-executive directors and meet at least once annually, with the flexibility to convene more frequently if needed, ensuring a structured and transparent process for Board nominations and governance.

The most recent analyst rating on (HK:9955) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on ClouDr Group Limited stock, see the HK:9955 Stock Forecast page.

ClouDr Group Reports Significant Revenue Decline and Increased Losses in H1 2025

ClouDr Group Limited announced its unaudited consolidated interim results for the first half of 2025, revealing a significant decline in revenue and an increase in losses compared to the same period in 2024. The company’s revenue dropped by 58% to RMB 892,579,000, with notable decreases in its In-hospital and Value Added Solutions. Despite the overall financial downturn, the company experienced growth in its Subscription and P2M Solutions. Additionally, the announcement included the termination and initiation of certain discloseable transactions and a change in the composition of the Nomination Committee, which may impact the company’s strategic direction and governance.

The most recent analyst rating on (HK:9955) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on ClouDr Group Limited stock, see the HK:9955 Stock Forecast page.

ClouDr Group Limited Schedules Board Meeting to Review Interim Results

ClouDr Group Limited has announced that its board of directors will convene on August 27, 2025, to review and approve the interim financial results for the first half of the year ending June 30, 2025. This meeting is significant as it will provide insights into the company’s financial health and operational performance, potentially impacting its market positioning and stakeholder confidence.